Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Carcinoma, Transitional Cell × dactolisib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neuroendocrine Tumors 2 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Neoplasm Metastasis 1 Kidney Neoplasms 1 Glioblastoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

pembrolizumab 13 atezolizumab 8 Nivolumab 8 Gemcitabine 6 Docetaxel 5 avelumab 4 fludarabine 3 Mitomycin 3 Cyclophosphamide 3 Carboplatin 3 vofatamab 2 valrubicin 2 pemigatinib 2 enfortumab vedotin 2 durvalumab 2 cabozantinib 2 Standard of Care 2 Pemetrexed 2 B701 protein, Human herpesvirus 6 2 trilaciclib 1 sitravatinib 1 selinexor 1 rucaparib 1 poly ICLC 1 olaparib 1 gemcitabine-oxaliplatin regimen 1 erdafitinib 1 epacadostat 1 dactolisib 1 apatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01856101 2019-04-10

BEZ235

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 2 Terminated

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡